• Complicated intra-abdominal infections (in combination with metronidazole).
• Complicated urinary tract infections (including pyelonephritis).
• Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Contraindicated in:

• Known serious hypersensitivity to ceftolozane/tazobactam, piperacillin/tazobactam or other beta-lactams
• Pedi: eGFR ≤50 mL/min/1.73 m².

Use Cautiously in:

• CCr 30–<50 mL/min (effectiveness may be ↓ in adults)
• CCr <50 mL/min (dose adjustment recommended in adults)
• OB: Use during pregnancy only if potential benefit outweighs potential risks
• Lactation: Use cautiously if breastfeeding

CV: atrial fibrillation, hypotension.

Derm: rash.

F and E: hypokalemia.

GI: diarrhea, abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, nausea, vomiting.

Hemat: anemia, thrombocytosis.

Neuro: anxiety, dizziness, headache, insomnia.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).

Drug-Drug:

• None reported.

• Powder for injection: 1 g ceftolozane/0.5 g tazobactam/vial;

Complicated Intra-abdominal Infections or Complication Urinary Tract Infections

• IV (Adults): 1.5 g (1 g ceftolozane/0.5 g tazobactam) every 8 hr for 4–14 days for complicated intra-abdominal infection or 7 days for complicated urinary tract infection.
• IV (Children <18 yr and eGFR >50 mL/min/1.73 m²): 30 mg/kg (max dose = 1.5 g) every 8 hr for 5–14 days for complicated intra-abdominal infection or 7–14 days for complicated urinary tract infection.

Hospital-acquired Bacterial Pneumonia or Ventilator-associated Bacterial Pneumonia

• IV (Adults): 3 g (2 g ceftolozane/1 g tazobactam) every 8 hr for 8–14 days.

Zerbaxa

• Ceftolozane: binds to bacterial cell wall membrane, causing cell death. Spectrum is extended compared with other penicillins. Tazobactam: Inhibits beta-lactamase, an enzyme that can destroy penicillins.

• Death of susceptible bacteria.

Spectrum:

• Active against Bacteroides fragilis, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcesens, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius.

Therapeutic Classification: anti-infectives

Pharmacologic Classification:

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Ceftolozane: minimal metabolism, excreted almost entirely (>95%) unchanged in urine; tazobactam: 80% excreted unchanged in urine, some metabolized to an inactive M1 metabolite which is excreted unchanged in urine.

Half-life: Ceftolozane: 2.8 hr; tazobactam: 0.9 hr.

• Explain the purpose of ceftolozane/tazobactam to patient.
• Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
• Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

sef-TOL-o-zane/taz-oh-BAK-tam

NDC Code^*

• 67919- Merck Sharp and Dohme Corp.
  • 67919-030- ZERBAXA
    • 67919-030-01- 10 VIAL, SINGLE-DOSE in 1 CARTON (67919-030-01) > 10 mL in 1 VIAL, SINGLE-DOSE